Supernus Pharmaceuticals, Inc. $SUPN Stake Raised by Martingale Asset Management L P

Martingale Asset Management L P grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 28.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 57,199 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,607 shares during the quarter. Martingale Asset Management L P’s holdings in Supernus Pharmaceuticals were worth $1,873,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $25,000. Financial Management Professionals Inc. bought a new stake in Supernus Pharmaceuticals during the first quarter worth approximately $30,000. Versant Capital Management Inc raised its holdings in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Supernus Pharmaceuticals during the first quarter worth approximately $41,000. Finally, GF Fund Management CO. LTD. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $42,000.

Analyst Upgrades and Downgrades

SUPN has been the topic of several recent analyst reports. Wall Street Zen raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total value of $315,132.82. Following the transaction, the director owned 46,307 shares in the company, valued at approximately $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 140,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the completion of the transaction, the chief executive officer owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. This trade represents a 11.96% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 152,826 shares of company stock worth $6,424,773. 8.80% of the stock is owned by insiders.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $44.88 on Friday. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of 39.03 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $45.01. The firm’s 50 day moving average price is $35.41 and its two-hundred day moving average price is $33.73.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.